MA28827B1 - Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases - Google Patents

Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases

Info

Publication number
MA28827B1
MA28827B1 MA29719A MA29719A MA28827B1 MA 28827 B1 MA28827 B1 MA 28827B1 MA 29719 A MA29719 A MA 29719A MA 29719 A MA29719 A MA 29719A MA 28827 B1 MA28827 B1 MA 28827B1
Authority
MA
Morocco
Prior art keywords
aminohetero
kinases
pyrazole
inhibitors
protein
Prior art date
Application number
MA29719A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Lee Andrew Funk
Lei Jia
Pei-Pei Kung
Jerry Jialun Meng
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA28827B1 publication Critical patent/MA28827B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
MA29719A 2004-08-26 2007-02-26 Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases MA28827B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60524404P 2004-08-26 2004-08-26
US69080305P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
MA28827B1 true MA28827B1 (fr) 2007-08-01

Family

ID=35677463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29719A MA28827B1 (fr) 2004-08-26 2007-02-26 Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases

Country Status (43)

Country Link
US (1) US20060128724A1 (fr)
EP (1) EP1784396B8 (fr)
JP (1) JP4167295B2 (fr)
KR (1) KR100869393B1 (fr)
CN (1) CN101018780B (fr)
AP (1) AP2332A (fr)
AR (1) AR050529A1 (fr)
AT (1) ATE492544T1 (fr)
AU (1) AU2005276132B2 (fr)
BR (1) BRPI0514537B8 (fr)
CA (1) CA2577937C (fr)
CR (2) CR8938A (fr)
CY (1) CY1111138T1 (fr)
DE (1) DE602005025499D1 (fr)
DK (1) DK1784396T3 (fr)
EA (1) EA011725B1 (fr)
EC (1) ECSP077278A (fr)
ES (1) ES2355923T3 (fr)
GE (1) GEP20094845B (fr)
GT (1) GT200500226A (fr)
HN (1) HN2005000477A (fr)
HR (1) HRP20110116T1 (fr)
IL (1) IL181045A0 (fr)
MA (1) MA28827B1 (fr)
ME (1) ME01309B (fr)
MX (1) MX2007002310A (fr)
MY (1) MY139942A (fr)
NI (1) NI200700058A (fr)
NL (1) NL1029809C2 (fr)
NO (1) NO338656B1 (fr)
NZ (1) NZ552946A (fr)
PA (1) PA8643201A1 (fr)
PE (1) PE20060651A1 (fr)
PL (1) PL1784396T3 (fr)
PT (1) PT1784396E (fr)
RS (1) RS51601B (fr)
SI (1) SI1784396T1 (fr)
SV (1) SV2006002208A (fr)
TN (1) TNSN07071A1 (fr)
TW (1) TWI300411B (fr)
UY (1) UY29080A1 (fr)
WO (1) WO2006021881A2 (fr)
ZA (1) ZA200701281B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
GEP20104906B (en) * 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
BRPI0619424B1 (pt) * 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
KR101146852B1 (ko) * 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
CA2667428A1 (fr) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazoles bicycliques en tant que modulateurs de proteine kinase
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
MY148851A (en) 2006-12-14 2013-06-14 Bayer Ip Gmbh Dihydropyridine derivatives as useful as protein kinase inhibitors
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
CN101855342B (zh) 2007-09-13 2013-07-10 科德克希思公司 用于还原苯乙酮的酮还原酶多肽
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
EP2265270A1 (fr) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CN102015660A (zh) 2008-04-23 2011-04-13 协和发酵麒麟株式会社 2-氨基喹唑啉衍生物
KR101034351B1 (ko) * 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
CA2728408C (fr) 2008-06-19 2017-12-05 Congxin Liang Composes de pyridazinecarboxamide substitues utiles en tant que composes inhibiteurs de kinase
WO2010059771A1 (fr) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
EP2435444A1 (fr) * 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Inhibiteurs à base de pyrazole substitué de la protéine kinase c-met
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
JP2013519681A (ja) * 2010-02-11 2013-05-30 オーエスアイ・ファーマシューティカルズ，エルエルシー ７−アミノフロピリジン誘導体
ES2509951T3 (es) * 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
US20120329826A1 (en) 2010-03-03 2012-12-27 OSI Pharmaceuticals,. LLC Substituted-5-aminopyrrolo/pyrazolopyridines
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
EP3450432A1 (fr) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Nouveaux composés 3,5 disubstitués-3h-imidazo[4,5-b] pyridine et 3,5-disubstitués-3h-[1,2,3]triazolo[4,5-b] pyridine utilisés comme modulateurs de kinases de protéine
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
JP5810157B2 (ja) * 2010-07-09 2015-11-11 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ プロテインキナーゼ阻害剤および処置の方法
CN101967140A (zh) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 氘代克里唑蒂尼及其衍生物、制备方法和应用
US9126947B2 (en) 2010-10-08 2015-09-08 Xcovery Holding Company Llc Substituted pyridazine carboxamide compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
EP2691384B1 (fr) 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
EP2710003A1 (fr) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
WO2013013308A1 (fr) * 2011-07-27 2013-01-31 Beta Pharma Canada Inc. Molécules spirocycliques convenant comme inhibiteurs de protéines kinases
HK1198133A1 (en) 2011-08-02 2015-03-13 辉瑞公司 Crizotinib for use in the treatment of cancer
US20140350050A1 (en) * 2011-09-21 2014-11-27 Teligene Ltd. Pyridine compounds as inhibitors of kinase
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
WO2013132376A1 (fr) 2012-03-06 2013-09-12 Pfizer Inc. Dérivés macrocycliques pour le traitement de maladies prolifératives
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2013138210A1 (fr) * 2012-03-14 2013-09-19 Ning Xi Composés cycliques substitués et procédés d'utilisation
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
WO2013144191A1 (fr) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh 2-amino-3-cyanopyridines substituées utilisées comme inhibiteurs de l'échange sodium-calcium et leurs utilisations dans le cas de maladies cardiovasculaires
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
CN103373986B (zh) * 2012-04-22 2016-10-05 东南大学 克里唑替尼前药及其制备方法与用途
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
WO2013181251A1 (fr) 2012-05-29 2013-12-05 Ratiopharm Gmbh Sel de chlorhydrate de crizotinib sous forme cristalline
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014020467A2 (fr) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Procédé de préparation de composés d'aminohétéroaryle à substitution pyrazole
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CA2883985A1 (fr) 2012-08-27 2014-03-06 Cemm-Forschungszentrum Fur Molekulare Medezin Gmbh Composes aminoheteroaryles en tant qu'inhibiteurs de mth1
CN103720691A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
WO2014081816A1 (fr) * 2012-11-21 2014-05-30 Concert Pharmaceuticals, Inc. Dérivés fluorés de composés amino-hétéroaryle substitués par pyrazole
MX2015009270A (es) * 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
RU2671212C2 (ru) * 2013-02-02 2018-10-30 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд Замещенный 2-аминопиридин в качестве ингибитора протеинкиназы
CN103992307B (zh) * 2013-02-16 2017-07-14 浙江九洲药物科技有限公司 一种克里唑替尼的制备方法
WO2014139391A1 (fr) * 2013-03-11 2014-09-18 Teligene Ltd Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases
EP2970181B1 (fr) 2013-03-14 2017-06-07 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
WO2014153226A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
EP2970136A1 (fr) 2013-03-14 2016-01-20 Epizyme, Inc. Inhibteurs de l'arginine méthyltransférase et utilisations de ceux-ci
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970131B1 (fr) 2013-03-14 2017-11-15 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
CN104059054B (zh) * 2013-03-19 2018-11-20 浙江导明医药科技有限公司 用于治疗癌症的三级环状胺alk激酶抑制剂
WO2014203177A1 (fr) * 2013-06-18 2014-12-24 Shilpa Medicare Limited (r)-3-[1-(2,6-dichloro-3-fluorophényl)méthoxy]-5-[1-(pipéridin-4-yl)-1h-pyrazol-4-yl]pyridine-2-amine amorphe
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
KR101598664B1 (ko) 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
WO2015034729A1 (fr) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Composés de pyridine substituée et leurs méthodes d'utilisation
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AU2013402175B2 (en) 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015172747A1 (fr) * 2014-05-16 2015-11-19 Zhaoyin Wang Molécules spirocycliques servant d'inhibiteurs de mth1
CA2955676A1 (fr) 2014-08-25 2016-03-03 Pfizer Inc. Combinaison d'un antagoniste de pd-1 et d'un inhibiteur d'alk dans le traitement du cancer
WO2016044576A1 (fr) * 2014-09-17 2016-03-24 Epizyme, Inc. Sels, co-cristaux, formes amorphes, et formes cristallines d'un inhibiteur d'arginine méthyltransférase
CN104402868B (zh) * 2014-11-04 2016-08-24 郑州泰基鸿诺医药股份有限公司 氘代克里唑蒂尼晶型及其制备方法
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
WO2016145383A1 (fr) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Inhibiteurs de mth1 pour le traitement de maladies
CN111440189B (zh) 2015-04-24 2022-08-09 广州再极医药科技有限公司 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
CN106279112A (zh) * 2015-06-12 2017-01-04 浙江九洲药业股份有限公司 一种克里唑替尼中间体及其制备方法和应用
CA3000386A1 (fr) 2015-09-30 2017-04-06 Merck Patent Gmbh Combinaison d'un antagoniste de la liaison de l'axe pd-1 et d'un inhibiteur de alk dans le traitement du cancer alk-negatif
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
CA3063976A1 (fr) 2017-05-23 2018-11-29 Mei Pharma, Inc. Polytherapie
WO2019036489A1 (fr) 2017-08-14 2019-02-21 Mei Pharma, Inc. Polythérapie
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
KR102207608B1 (ko) 2019-04-24 2021-01-26 윤종오 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품
CN115745979B (zh) * 2021-11-11 2025-09-23 中国医学科学院医药生物技术研究所 一种蛋白靶向降解化合物及其用途
EP4552648A1 (fr) 2022-07-04 2025-05-14 Chugai Seiyaku Kabushiki Kaisha Association médicamenteuse
WO2024048555A1 (fr) 2022-08-30 2024-03-07 中外製薬株式会社 Médicament d'association

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (fr) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU2710597A (en) * 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
ATE289602T1 (de) * 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
EP1006113A1 (fr) * 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
US6586447B1 (en) * 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1081137A1 (fr) * 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
DE60008206T2 (de) * 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1472237A4 (fr) * 2002-02-06 2006-01-11 Yissum Res Dev Co Bioisosteres du catechol
AU2003246927A1 (en) * 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
AU2003247141A1 (en) * 2002-08-01 2004-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE10307845A1 (de) * 2003-02-25 2004-09-02 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
GEP20104906B (en) * 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
ES2355923T3 (es) 2011-04-01
CN101018780B (zh) 2012-01-11
KR20070038569A (ko) 2007-04-10
RS51601B (sr) 2011-08-31
EP1784396B1 (fr) 2010-12-22
ECSP077278A (es) 2007-03-29
TWI300411B (en) 2008-09-01
TW200621751A (en) 2006-07-01
GT200500226A (es) 2006-04-10
HRP20110116T1 (hr) 2011-03-31
EP1784396B8 (fr) 2011-04-20
EA011725B1 (ru) 2009-04-28
NO20071320L (no) 2007-05-29
SI1784396T1 (sl) 2011-03-31
DE602005025499D1 (de) 2011-02-03
PE20060651A1 (es) 2006-07-19
NL1029809C2 (nl) 2006-10-17
BRPI0514537B1 (pt) 2020-05-12
KR100869393B1 (ko) 2008-11-21
CA2577937A1 (fr) 2006-03-02
CN101018780A (zh) 2007-08-15
IL181045A0 (en) 2007-07-04
PA8643201A1 (es) 2006-06-02
ZA200701281B (en) 2008-12-31
SV2006002208A (es) 2006-10-04
EA200700321A1 (ru) 2007-08-31
WO2006021881A3 (fr) 2006-05-18
AU2005276132A1 (en) 2006-03-02
BRPI0514537B8 (pt) 2021-05-25
MY139942A (en) 2009-11-30
PL1784396T3 (pl) 2011-05-31
PT1784396E (pt) 2011-01-27
WO2006021881A2 (fr) 2006-03-02
NL1029809A1 (nl) 2006-02-28
HN2005000477A (es) 2010-06-09
BRPI0514537A (pt) 2008-06-17
CR8938A (es) 2007-08-14
AP2332A (en) 2011-12-05
NO338656B1 (no) 2016-09-26
JP4167295B2 (ja) 2008-10-15
CA2577937C (fr) 2010-12-21
HK1105415A1 (en) 2008-04-03
NZ552946A (en) 2010-09-30
AP2007003906A0 (en) 2007-02-28
AR050529A1 (es) 2006-11-01
DK1784396T3 (da) 2011-02-14
GEP20094845B (en) 2009-11-25
MX2007002310A (es) 2007-05-08
EP1784396A2 (fr) 2007-05-16
US20060128724A1 (en) 2006-06-15
ME01309B (me) 2013-12-20
NI200700058A (es) 2008-03-07
CY1111138T1 (el) 2015-06-11
CR20120421A (es) 2012-09-14
ATE492544T1 (de) 2011-01-15
JP2008510788A (ja) 2008-04-10
AU2005276132B2 (en) 2011-09-29
UY29080A1 (es) 2006-03-31
TNSN07071A1 (fr) 2008-06-02

Similar Documents

Publication Publication Date Title
EP1732906A4 (fr) Composes de 2-aminothiazole utiles en tant qu'inhibiteurs de l'aspartyle-protease
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
MA28828B1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
EP2228378A4 (fr) Monosébacate d'un dérivé de pyrazole
MA28393B1 (fr) Dérivés de triazole servant d'antagonistes de la vasopressine
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
EP1663112A4 (fr) Compositions d'opioides intranasales
EP1609089A4 (fr) Annotation d'un formulaire de demande de modification
MA28798B1 (fr) Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
EP1940393A4 (fr) Dérivés de triazol en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase-1
EP1765336A4 (fr) Inhibiteurs d'angiogenese
IL198089A0 (en) An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure
SMP200800059B (it) Chinazoline per l'inibizione di pdk1
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
EP1746141A4 (fr) Composition d' epaississement
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
EP1689739A4 (fr) Inhibiteurs de kinases a base d'azole
FR2871145B1 (fr) Distributeur d'applicateurs
MA28543B1 (fr) Dérivés d'imidazole utilisés comme inhibiteurs tafia
EP1694339A4 (fr) Utilisation de composes a base de 9-desoxoerythromycine comme agents procinetiques
EP1776863A4 (fr) Composition chimique pour l'agriculture
EP1957474A4 (fr) Synthese d'inhibiteurs de ftfz
ATE365161T1 (de) Pyrazolverbindungen
EP1906962A4 (fr) Composes d'octahydroisoquinoleine comme modulateurs de recepteurs opioides
EP1603900A4 (fr) Composes d'imidazopyridine antiprotozoaires